Human TRAIL R4 / CD264 / TNFRSF10D Protein (His & Fc Tag)
CD264,DCR2,TRAIL-R4,TRAILR4,TRUNDD
- 100ug (NPP4339) Please inquiry
| Catalog Number | P10413-H03H |
|---|---|
| Organism Species | Human |
| Host | Human Cells |
| Synonyms | CD264,DCR2,TRAIL-R4,TRAILR4,TRUNDD |
| Molecular Weight | The recombinant human TNFRSF10D/Fc is a disulfide-linked homodimeric protein after removal of the signal peptide. The reduced monomer consists of 403 amino acids and predicts a molecular mass of 44.7 kDa. As a result of glycosylation, rhTNFRSF10D/Fc monomer migrates with the molecular mass of approximately 65-80 kDa in SDS-PAGE under reducing conditions. |
| predicted N | Ala 56 |
| SDS-PAGE |  |
| Purity | > 98 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the extracellular domain (Met 1-His 211) of humanTNFRSF10D (NP_003831.2) was fused with the C-terminal His-tagged Fc region of human IgG1 at the C-terminus. |
| Bio-activity | 1. Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF10D Fc Chimera at 10 μg/ml (100 μl/well) can bind biotinylated TNFSF10 with a linear range of 0.625-20 ng/ml. 2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 0.2-1 μg/mL in the presence of 20 ng/ml Recombinant Human TRAIL/TNFSF10. |
| Research Area | Cancer |Signal transduction |Growth Factor & Receptor |Tumor Necrosis Factor (TNF) & Receptor |TNF Receptor |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF10D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF10D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity. |
| Reference |